Accéder au contenu
Merck

Electrotransfection and lipofection show comparable efficiency for in vitro gene delivery of primary human myoblasts.

The Journal of membrane biology (2014-12-24)
Tomaz Mars, Marusa Strazisar, Katarina Mis, Nejc Kotnik, Katarina Pegan, Jasna Lojk, Zoran Grubic, Mojca Pavlin
RÉSUMÉ

Transfection of primary human myoblasts offers the possibility to study mechanisms that are important for muscle regeneration and gene therapy of muscle disease. Cultured human myoblasts were selected here because muscle cells still proliferate at this developmental stage, which might have several advantages in gene therapy. Gene therapy is one of the most sought-after tools in modern medicine. Its progress is, however, limited due to the lack of suitable gene transfer techniques. To obtain better insight into the transfection potential of the presently used techniques, two non-viral transfection methods--lipofection and electroporation--were compared. The parameters that can influence transfection efficiency and cell viability were systematically approached and compared. Cultured myoblasts were transfected with the pEGFP-N1 plasmid either using Lipofectamine 2000 or with electroporation. Various combinations for the preparation of the lipoplexes and the electroporation media, and for the pulsing protocols, were tested and compared. Transfection efficiency and cell viability were inversely proportional for both approaches. The appropriate ratio of Lipofectamine and plasmid DNA provides optimal conditions for lipofection, while for electroporation, RPMI medium and a pulsing protocol using eight pulses of 2 ms at E = 0.8 kV/cm proved to be the optimal combination. The transfection efficiencies for the optimal lipofection and optimal electrotransfection protocols were similar (32 vs. 32.5%, respectively). Both of these methods are effective for transfection of primary human myoblasts; however, electroporation might be advantageous for in vivo application to skeletal muscle.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Phosphate de potassium monobasic, ACS reagent, ≥99.0%
Sigma-Aldrich
Phosphate de potassium dibasic, ACS reagent, ≥98%
Sigma-Aldrich
Phosphate de potassium monobasic, powder, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99.0%
Sigma-Aldrich
L-Glutathion réduit, suitable for cell culture, BioReagent, ≥98.0%, powder
Sigma-Aldrich
Phosphate de potassium monobasic, for molecular biology, ≥98.0%
Sigma-Aldrich
Phosphate de potassium dibasic, anhydrous, for luminescence, for molecular biology, BioUltra, ≥99.0% (T)
Sigma-Aldrich
Potassium phosphate dibasic solution, 1.0 M
Sigma-Aldrich
Phosphate de potassium monobasic, BioUltra, for molecular biology, anhydrous, ≥99.5% (T)
Sigma-Aldrich
L-Glutathion réduit, ≥98.0%
Sigma-Aldrich
Phosphate de potassium monobasic, 99.99% trace metals basis
Sigma-Aldrich
Phosphate de potassium dibasic, 99.95% trace metals basis
Sigma-Aldrich
Phosphate de potassium monobasic, ReagentPlus®
USP
Phosphate de potassium monobasic, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Phosphate de potassium dibasic, reagent grade, ≥98.0%
Supelco
L-Glutathion réduit, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Phosphate de potassium dibasic, meets USP testing specifications
Sigma-Aldrich
L-Glutathion réduit, BioXtra, ≥98.0%
Supelco
Phosphate de potassium monobasic, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Phosphate de potassium monobasic, tested according to Ph. Eur., anhydrous
L-Glutathion réduit, European Pharmacopoeia (EP) Reference Standard